[FG] Liechti Matthias

McCulloch, D.E.-W. et al. (2025) ‘Molecular, haemodynamic and functional effects of LSD in the human brain’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2025.06.17.25329677.

Atila, C. et al. (2025) ‘The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial’, Endocrine Connections, 14(6). Available at: https://doi.org/10.1530/ec-25-0254.

Pronovost-Morgan, Chloé et al. (2025) ‘An international Delphi consensus for reporting of setting in psychedelic clinical trials’, Nature Medicine [Preprint]. Available at: https://doi.org/10.1038/s41591-025-03685-9.

Kraus, E. et al. (2025) ‘Case report: Well-tolerated MDMA-assisted therapy in a 32-year old female patient with advanced alcohol-induced liver cirrhosis’, Psychiatry Research Case Reports, 4(1), p. 100252. Available at: https://doi.org/10.1016/j.psycr.2025.100252.

Müller, Felix et al. (2025) ‘Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial’, Med, p. 100725. Available at: https://doi.org/10.1016/j.medj.2025.100725.

Arikci, D. et al. (2025) ‘Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study’, Clinical Pharmacology & Therapeutics [Preprint]. Available at: https://doi.org/10.1002/cpt.3726.

Erne, Livio et al. (2025) ‘Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants’, Neuropsychopharmacology, 50(6), pp. 1008–1016. Available at: https://doi.org/10.1038/s41386-024-02041-8.

Atila, C. et al. (2025) ‘Neurophysin I: a reliable, novel, and robust biomarker for oxytocin’, European Journal of Endocrinology, 192(4), pp. 502–510. Available at: https://doi.org/10.1093/ejendo/lvaf078.

Avram, Mihai et al. (2025) ‘Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine’, Molecular Psychiatry, 30, pp. 1297–1307. Available at: https://doi.org/10.1038/s41380-024-02734-y.

Becker, Anna M. (2025) Interaction of Lysergic Acid Diethylamide and Psilocybin with Selective Serotonin Reuptake Inhibitors and Ketanserin. Doctoral Thesis. University of Basel.

Becker, A.M. et al. (2025) ‘Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial’, Clinical Pharmacology and Therapeutics [Preprint]. Available at: https://doi.org/10.1002/cpt.3618.

Gasser, P., Liechti, M.E. and Holze, F. (2025) ‘Treatment of neuropathic pain with repeated low-dose MDMA: a case report’, Frontiers in Psychiatry, 16. Available at: https://doi.org/10.3389/fpsyt.2025.1513022.

Guessoum, Adrian et al. (2025) ‘Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment for Severe Opioid Use Disorder’, CNS Drugs [Preprint]. Available at: https://doi.org/10.1007/s40263-025-01189-1.

LEY, LAURA (2025) Pharmacology, physiology, and psychology of serotonergic psychedelics in healthy participants. Doctoral Thesis. University of Basel.

Ley, L. et al. (2025) ‘Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers’, Psychopharmacology [Preprint]. Available at: https://doi.org/10.1007/s00213-025-06772-4.

Thomann, J. (2025) Bioanalysis and metabolic investigation of psychoactive substances. Doctoral Thesis.

Hutten, N.R.P.W. et al. (2024) ‘Inter-individual variability in neural response to low doses of LSD’, Translational Psychiatry, 14(1). Available at: https://doi.org/10.1038/s41398-024-03013-8.

Klaiber, A. et al. (2024) ‘Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects’, Translational Psychiatry, 14(1). Available at: https://doi.org/10.1038/s41398-024-03116-2.

Straumann, I. et al. (2024) ‘Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants’, Neuropsychopharmacology, 50(2), pp. 362–371. Available at: https://doi.org/10.1038/s41386-024-01972-6.

Vizeli, Patrick et al. (2024) ‘Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants’, Translational Psychiatry, 14. Available at: https://doi.org/10.1038/s41398-024-03074-9.

Atila, Cihan et al. (2024) ‘Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials’, JAMA network open, 7(11). Available at: https://doi.org/10.1001/jamanetworkopen.2024.45278.

Holze, F. et al. (2024) ‘Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research’, European Neuropsychopharmacology, 88, pp. 43–48. Available at: https://doi.org/10.1016/j.euroneuro.2024.07.003.

Kamau, Yvonne et al. (2024) ‘Mosquitocidal efficacy and pharmacokinetics of single-dose ivermectin versus three-day dose regimen for malaria vector control compared with albendazole and no treatment: An open-label randomized controlled trial’, International Journal of Infectious Diseases, 148, p. 107236. Available at: https://doi.org/10.1016/j.ijid.2024.107236.

Calder, A.E. et al. (2024) ‘Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response’, Journal of Psychopharmacology, 38(10), pp. 873–886. Available at: https://doi.org/10.1177/02698811241278873.

Angerer, Verena et al. (2024) ‘Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study’, Drug Testing and Analysis, 16(9), pp. 1002–1011. Available at: https://doi.org/10.1002/dta.3622.

Holze, F. et al. (2024) ‘LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up’, British Journal of Psychiatry, 225(3), pp. 362–370. Available at: https://doi.org/10.1192/bjp.2024.99.

Arias, H.R. et al. (2024) ‘Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT2A receptor activation’, Biomedicine and Pharmacotherapy, 177. Available at: https://doi.org/10.1016/j.biopha.2024.116867.

Stocker, K. and Liechti, M.E. (2024) ‘Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate”’, Journal of Psychopharmacology, 38(8), pp. 685–689. Available at: https://doi.org/10.1177/02698811241265352.

Müller-Durovic, Bojana et al. (2024) ‘A metabolic dependency of EBV can be targeted to hinder B cell transformation’, Science (New York, N.Y.), 385(6704). Available at: https://doi.org/10.1126/science.adk4898.

Anliker-Ort, Marion et al. (2024) ‘Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva – A Case Study’, Journal of Clinical Pharmacology, 64(7), pp. 810–819. Available at: https://doi.org/10.1002/jcph.2428.

Anliker‐Ort, Marion et al. (2024) ‘Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva – A Case Study’, Journal of Clinical Pharmacology, 64(7), pp. 810–819. Available at: https://doi.org/10.1002/jcph.2428.

Walz, Annabelle et al. (2024) ‘In vivo antimalarial efficacy of Artemisia afra powder suspensions’, Phytomedicine, 129. Available at: https://doi.org/10.1016/j.phymed.2024.155644.

Dao, Kim et al. (2024) ‘Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use’, The Journal of Clinical Pharmacology. 30.05.2024, 64(10), pp. 1295–1303. Available at: https://doi.org/10.1002/jcph.2462.

Blukacz, Lauriane et al. (2024) ‘Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC’, Hepatology Communications, 8(5). Available at: https://doi.org/10.1097/HC9.0000000000000437.

Atila, Cihan et al. (2024) ‘Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls’, European Journal of Endocrinology, 190(5), pp. 354–362. Available at: https://doi.org/10.1093/ejendo/lvae040.

Avram, Mihai et al. (2024) ‘Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration’, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 9(5), pp. 522–532. Available at: https://doi.org/10.1016/j.bpsc.2023.07.010.

de Wit, Harriet, Holze, Friederike and Preller, Katrin H. (2024) ‘Psychedelics in Medicine: Can Evidence Keep Up With Enthusiasm?’, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 9(5), pp. 460–461. Available at: https://doi.org/10.1016/j.bpsc.2024.02.010.

Holze, Friederike et al. (2024) ‘Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile’, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 9(5), pp. 472–489. Available at: https://doi.org/10.1016/j.bpsc.2024.01.007.

Luethi, Dino et al. (2024) ‘Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers’, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1238. Available at: https://doi.org/10.1016/j.jchromb.2024.124123.

Thomann, Jan et al. (2024) ‘Development and validation of an LC-MS/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma’, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1237, p. 124104. Available at: https://doi.org/10.1016/j.jchromb.2024.124104.

Thomann, Jan et al. (2024) ‘Development and validation of an LC-MS/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma’, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1237. Available at: https://doi.org/10.1016/j.jchromb.2024.124104.

Arias, Hugo R. et al. (2024) ‘The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT2A receptor activation’, European Journal of Pharmacology, 966. Available at: https://doi.org/10.1016/j.ejphar.2024.176329.

Abegg, Vanessa Fabienne et al. (2024) ‘Mechanisms of hepatocellular toxicity associated with the components of St. John’s Wort extract hypericin and hyperforin in HepG2 and HepaRG cells’, Toxicology Letters, 393, pp. 1–13. Available at: https://doi.org/10.1016/j.toxlet.2024.01.008.

Atila, C. et al. (2024) ‘Oxytocin, Not Vasopressin, Mediates High Incidence of MDMA-Induced Hyponatremia - A Complication Preventable by Fluid Restriction’. Elsevier BV. Available at: https://doi.org/10.2139/ssrn.4819307.

Holze, Friederike et al. (2024) ‘Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants’, British Journal of Clinical Pharmacology, 90(1), pp. 200–208. Available at: https://doi.org/10.1111/bcp.15887.

Holze, F., Liechti, M.E. and Müller, F. (2024) ‘Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms’, in Current Topics in Behavioral Neurosciences. Berlin, Heidelberg: Springer Berlin Heidelberg (Current Topics in Behavioral Neurosciences). Available at: https://doi.org/10.1007/7854_2024_510.

E-Wen McCulloch, D. et al. (2024) ‘Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects’, Neuroscience Applied, 3, p. 103938. Available at: https://doi.org/10.1016/j.nsa.2024.103938.

Liechti, Matthias E. (2024) ‘Psychedelics as medication?’, Revue Medicale Suisse, 20, pp. 118–119. Available at: https://doi.org/10.53738/revmed.2024.20.858.118.

Stocker, Kurt et al. (2024) ‘The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies’, Journal of Psychopharmacology, 38(1), pp. 80–100. Available at: https://doi.org/10.1177/02698811231199112.

Straumann, I. et al. (2024) ‘Safety pharmacology of acute psilocybin administration in healthy participants’, Neuroscience Applied, 3, p. 104060. Available at: https://doi.org/10.1016/j.nsa.2024.104060.

Thomann, Jan et al. (2024) ‘In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin’, Frontiers in Pharmacology, 15. Available at: https://doi.org/10.3389/fphar.2024.1391689.

Thomann, Jan et al. (2024) ‘In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin’, Frontiers in Pharmacology, 15. Available at: https://doi.org/10.3389/fphar.2024.1391689.

Waters, M.L. et al. (2024) ‘Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020’, Clinical Toxicology, 62(6), pp. 378–384. Available at: https://doi.org/10.1080/15563650.2024.2346125.

Waters, Mitchell L. et al. (2024) ‘Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020’, Clinical Toxicology, 62(6), pp. 378–384. Available at: https://doi.org/10.1080/15563650.2024.2346125.

Straumann, Isabelle et al. (2023) ‘Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants’, Neuropsychopharmacology, 48(13), pp. 1840–1848. Available at: https://doi.org/10.1038/s41386-023-01609-0.

Vallersnes, O.M. et al. (2023) ‘Self-discharge during treatment for acute recreational drug toxicity: an observational study from emergency departments in seven European countries’, International Journal of Emergency Medicine, 16(1). Available at: https://doi.org/10.1186/s12245-023-00566-1.

Vogt, Severin B. et al. (2023) ‘Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants’, Translational Psychiatry, 13(1). Available at: https://doi.org/10.1038/s41398-023-02477-4.

Ley, Laura et al. (2023) ‘Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants’, Neuropsychopharmacology, 48(11), pp. 1659–1667. Available at: https://doi.org/10.1038/s41386-023-01607-2.

Ley, Laura et al. (2023) ‘Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants’, Neuropsychopharmacology, 48(11), pp. 1659–1667. Available at: https://doi.org/10.1038/s41386-023-01607-2.

Noseda, Roberta et al. (2023) ‘Determinants of Admission to Critical Care Following Acute Recreational Drug Toxicity: A Euro-DEN Plus Study’, Journal of Clinical Medicine, 12(18). Available at: https://doi.org/10.3390/jcm12185970.

Atila, Cihan et al. (2023) ‘Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial’, The Lancet Diabetes and Endocrinology, 11(7), pp. 454–464. Available at: https://doi.org/10.1016/S2213-8587(23)00120-1.

Bedford, Peter et al. (2023) ‘The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity’, Neuropsychopharmacology, 48(8), pp. 1175–1183. Available at: https://doi.org/10.1038/s41386-023-01574-8.

Anderson, C.E. et al. (2023) ‘Temporal development of unfavourable urodynamic parameters during the first year after spinal cord injury’, BJU International, 131(4), pp. 503–512. Available at: https://doi.org/10.1111/bju.15918.

Holze, Friederike et al. (2023) ‘Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants’, Clinical Pharmacology and Therapeutics, 113(4), pp. 822–831. Available at: https://doi.org/10.1002/cpt.2821.

Becker, Anna M. et al. (2023) ‘Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants’, International Journal of Neuropsychopharmacology, 26(2), pp. 97–106. Available at: https://doi.org/10.1093/ijnp/pyac075.

Holze, Friederike et al. (2023) ‘Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study’, Biological Psychiatry, 93(3), pp. 215–223. Available at: https://doi.org/10.1016/j.biopsych.2022.08.025.

Miró, Òscar et al. (2023) ‘Severity of emergency department presentations due to acute drug toxicity in Europe: A longitudinal analysis over a 6-year period (2014-2019) stratified by sex’, European Journal of Emergency Medicine, 30(1), pp. 21–31. Available at: https://doi.org/10.1097/MEJ.0000000000000978.

Felix Müller et al. (2023) ‘Lysergic acid diethylamide for depression — a randomized, double-blind, low dose-controlled phase ii trial’, in 36th ECNP Congress. Barcelona (36th ECNP Congress). Available at: https://doi.org/10.1016/j.nsa.2023.103912.

Halberstadt, Adam L. et al. (2023) ‘Use of the head-twitch response to investigate the structure–activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines’, Psychopharmacology, 240(1), pp. 115–126. Available at: https://doi.org/10.1007/s00213-022-06279-2.

Reissmann, Steffen et al. (2023) ‘Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study’, Frontiers in Psychiatry, 14. Available at: https://doi.org/10.3389/fpsyt.2023.1197697.

Rudin, Deborah et al. (2023) ‘Classic psychedelics do not affect T cell and monocyte immune responses’, Frontiers in Psychiatry, 14, p. 1042440. Available at: https://doi.org/10.3389/fpsyt.2023.1042440.

Luethi, Dino et al. (2022) ‘Liquid chromatography–tandem mass spectrometry method for the bioanalysis of N,N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma’, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1213. Available at: https://doi.org/10.1016/j.jchromb.2022.123534.

Luethi, Dino et al. (2022) ‘Phosphatidylinositol 4,5-bisphosphate (PIP2) facilitates norepinephrine transporter dimerization and modulates substrate efflux’, Communications Biology, 5(1). Available at: https://doi.org/10.1038/s42003-022-04210-1.

Bedford, P. et al. (2022) ‘The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2022.11.01.514687.

Thomann J et al. (2022) ‘Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma’, Journal of Pharmaceutical and Biomedical Analysis, 220, p. 114980. Available at: https://doi.org/10.1016/j.jpba.2022.114980.

Avram, Mihai et al. (2022) ‘Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration’, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 7(9), pp. 885–894. Available at: https://doi.org/10.1016/j.bpsc.2022.04.003.

Heier, Eva-Carina et al. (2022) ‘Clinical effect of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs’, European Journal of Emergency Medicine, 29(4), pp. 291–300. Available at: https://doi.org/10.1097/MEJ.0000000000000932.

Stocker K. et al. (2022) ‘Buddhist-like opposite diminishing and non-judging during ketamine infusion are associated with antidepressant response: an open-label personalized-dosing study’, Frontiers in Pharmacology, 13. Available at: https://doi.org/10.3389/fphar.2022.916641.

Vizeli P et al. (2022) ‘Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects’, Frontiers in Pharmacology, 13, p. 906639. Available at: https://doi.org/10.3389/fphar.2022.906639.

Kolaczynska K.E. et al. (2022) ‘Pharmacological characterization of 3,4-methylenedioxamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA’, European Neuropsychopharmacology, 59, pp. 9–22. Available at: https://doi.org/10.1016/j.euroneuro.2022.03.006.

Luethi D. and Liechti M.E. (2022) ‘Correction to: Designer drugs: mechanism of action and adverse effects (Archives of Toxicology, (2020), 94, 4, (1085-1133), 10.1007/s00204-020-02693-7)’, Archives of Toxicology, 96(5), p. 1489. Available at: https://doi.org/10.1007/s00204-022-03244-y.

Rudin, Deborah et al. (2022) ‘(2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice’, Neuropsychopharmacology, 47(4), pp. 914–923. Available at: https://doi.org/10.1038/s41386-021-01221-0.

Rudin D et al. (2022) ‘(2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice’, Neuropsychopharmacology, 47(4), pp. 914–923. Available at: https://doi.org/10.1038/s41386-021-01221-0.

Kleer JS et al. (2022) ‘Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus’, Frontiers in Immunology, 12, p. 761395. Available at: https://doi.org/10.3389/fimmu.2021.761395.

Becker, Anna M. et al. (2022) ‘Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects’, Clinical Pharmacology & Therapeutics, 111(4), pp. 886–895. Available at: https://doi.org/10.1002/cpt.2487.

Crulli, B. et al. (2022) ‘Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014–2019’, Clinical Toxicology, 60(12), pp. 1318–1327. Available at: https://doi.org/10.1080/15563650.2022.2137524.

Holze, Friederike et al. (2022) ‘Safety pharmacology of acute LSD administration in healthy subjects’, Psychopharmacology, 239(6), pp. 1893–1905. Available at: https://doi.org/10.1007/s00213-021-05978-6.

Holze, Friederike et al. (2022) ‘Correction to: Safety pharmacology of acute LSD administration in healthy subjects’, Psychopharmacology, 239(2), p. 661. Available at: https://doi.org/10.1007/s00213-021-05988-4.

Holze, Friederike et al. (2022) ‘Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects’, Neuropsychopharmacology, 47(6), pp. 1180–1187. Available at: https://doi.org/10.1038/s41386-022-01297-2.

Kolaczynska, Karolina E. et al. (2022) ‘Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines’, Frontiers in Pharmacology, 12, p. 794254. Available at: https://doi.org/10.3389/fphar.2021.794254.

Lett, Martin J et al. (2022) ‘Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells’, Gut, 71(12), pp. 2526–2538. Available at: https://doi.org/10.1136/gutjnl-2021-324478.

Müller, Felix et al. (2022) ‘Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants’, Psychopharmacology, 239(6), pp. 1933–1943. Available at: https://doi.org/10.1007/s00213-022-06066-z.

Preveden N et al. (2022) ‘Metamizole as a Rare Cause of Drug-Induced Liver Injury’, European Journal of Case Reports in Internal Medicine, 9(5). Available at: https://doi.org/10.12890/2022_003349.

Schmid Y et al. (2022) ‘Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex’, Clinical Toxicology, 60(8), pp. 912–919. Available at: https://doi.org/10.1080/15563650.2022.2060116.

Vogt S et al. (2021) ‘Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial’, Respiratory Research, 22(1), p. 227. Available at: https://doi.org/10.1186/s12931-021-01822-9.

Ruiz, A. et al. (2021) Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2021.11.09.467894.

Istampoulouoglou I et al. (2021) ‘Myocarditis and pericarditis in association with covid-19 mrna-vaccination: Cases from a regional pharmacovigilance centre’, Global Cardiology Science and Practice, 2021(3), p. e202118. Available at: https://doi.org/10.21542/gcsp.2021.18.

Bachmann, F. et al. (2021) ‘Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine’. Authorea, Inc. Available at: https://doi.org/10.22541/au.162544273.38681801/v1.

Camacho-Hernandez, Gisela Andrea et al. (2021) ‘Illuminating the norepinephrine transporter: fluorescent probes based on nisoxetine and talopram’, RSC Medicinal Chemistry, 12(7), pp. 1174–1186. Available at: https://doi.org/10.1039/d1md00072a.

Maier J et al. (2021) ‘α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and uptake1 and uptake2 monoamine transporters’, Neuropharmacology, 190, p. 108570. Available at: https://doi.org/10.1016/j.neuropharm.2021.108570.